BIO-RAD LABORATORIES, INC. (BIO-B)

Insider Trading Filed: 2026-05-13

Key Insights

Eva Anette Engelhardt, EVP and President of Clinical Diagnostics Group, sold 550 shares of Bio-Rad Class A common stock on May 11, 2026 at $246.54 per share, generating approximately $135,597 in proceeds.
Following the sale transaction, Engelhardt maintains direct beneficial ownership of 346 shares of Bio-Rad Class A common stock, indicating she retains a meaningful stake in the company despite the sale.
This represents a routine insider sale by a senior executive rather than a significant reduction in holdings, suggesting normal portfolio management or liquidity needs rather than loss of confidence in the company.

Current Report Filed: 2026-04-30

Key Insights

Bio-Rad announced Q1 2026 financial results on April 30, 2026, with earnings materials and supplemental presentation posted to the investor relations website for stakeholder review.
The filing indicates routine earnings disclosure without mention of material agreements, executive changes, or significant business developments, suggesting a standard quarterly reporting event.
Both Class A and Class B common stocks are registered on the NYSE, with the company maintaining dual-class share structure typical of founder-controlled life sciences firms.

Quarterly Report Filed: 2026-04-30

Key Insights

The filing shows Q1 2026 financial results for Bio-Rad Laboratories with comparative data from Q1 2025, indicating ongoing operations across multiple geographic segments (US, Europe, Americas, Asia-Pacific) with dual share class structure.
The company maintains a diversified investment portfolio including bank deposits, money market funds, US Treasury securities, corporate debt, and asset-backed securities, suggesting conservative cash management and liquidity planning.
The Stilla Technologies acquisition (referenced with June 30, 2025 valuation data) represents a strategic expansion into the life sciences segment, with fair value measurements indicating integration into the company's asset base.
Presence of accumulated other comprehensive income adjustments across quarters suggests exposure to foreign exchange fluctuations and investment valuation changes, which is material for a company with significant international operations.

Insider Trading Filed: 2026-04-28

Key Insights

CFO Roop Kalyan acquired 1,078 shares of Bio-Rad Class A common stock through vesting of restricted stock units on 04/24/2026, with total beneficial ownership reaching 2,983.895 shares, indicating continued equity accumulation by senior management.
The executive sold 420 shares at $287.84 per share on the same transaction date, suggesting either planned portfolio rebalancing or tax management rather than loss of confidence in the company.
RSU vesting represents routine compensation execution with 1,078 of 4,311 granted units vesting in the first annual installment (25%), consistent with standard four-year equity vesting schedules for senior executives.
The filing includes 62.24 shares acquired under the Employee Stock Purchase Plan on 03/31/2026, demonstrating the executive's voluntary participation in company savings programs alongside equity compensation.

Insider Trading Filed: 2026-04-28

Key Insights

EVP General Counsel Courtney Enloe acquired 186 shares through vesting of restricted stock units on 04/24/2026, with total beneficial ownership reaching 826.777 shares, indicating continued equity compensation alignment with company performance.
Simultaneous sale of 77 shares at $287.84 per share suggests routine portfolio rebalancing or tax management rather than loss of confidence, as the sale represents only ~9% of vested shares acquired.
RSU grant from April 2024 vests in four equal annual installments with 186 shares vesting in the first year, demonstrating a structured long-term executive retention strategy typical for senior leadership roles.
Additional share acquisitions through Bio-Rad Employee Stock Purchase Plan (09/30/2025 and 12/31/2025) totaling ~11.79 shares show voluntary participation in company equity programs beyond required compensation.

Current Report Filed: 2026-04-24

Key Insights

The company successfully increased its equity incentive pool by 335,000 shares and extended the plan expiration to March 2036, indicating confidence in long-term growth and ability to attract/retain talent through equity compensation.
Strong stockholder support for compensation practices with 96.2% approval of the advisory vote on executive compensation, suggesting alignment between management and shareholders on pay practices.
The dual class capital structure proposal was decisively rejected with 78.8% voting against, demonstrating shareholder preference for one-share-one-vote governance despite management's apparent support for maintaining dual classes.
All six director nominees were elected with substantial majorities, with Class A directors (Litherland and Pinkston) receiving 88.3% and 88.8% support respectively, reflecting strong board continuity and shareholder confidence.

Insider Trading Filed: 2026-04-23

Key Insights

Director Arnold Pinkston acquired 776 total shares of Bio-Rad Class A common stock through vesting of restricted stock units (369 shares on 04/21/2026 and 407 shares through an additional vesting event), indicating continued equity compensation alignment with shareholders.
The RSU vesting occurred at $0 price per share, confirming these were compensation-based equity awards rather than open market purchases, with vesting contingent on the earlier of the first anniversary or next annual stockholder meeting.
This transaction represents a routine insider equity compensation event with no significant buying or selling activity that would signal insider confidence or concern about the company's stock valuation.

Insider Trading Filed: 2026-04-23

Key Insights

Director Jeffrey L. Edwards acquired 407 shares of Bio-Rad Class A common stock on 04/21/2026 through the vesting of restricted stock units, with zero acquisition price indicating this was a compensation-related vesting event rather than a market purchase.
Edwards also received 369 additional restricted stock units on the same date, which will vest within one year or at the next annual stockholders meeting, demonstrating ongoing equity incentive compensation for board service.
The insider transaction shows routine equity compensation activity with no cash outlay, suggesting the director's stake in the company is being maintained through standard RSU vesting rather than voluntary market purchases, which is neutral from a conviction standpoint.

Insider Trading Filed: 2026-04-23

Key Insights

Director Gregory K. Hinckley acquired 407 shares of Bio-Rad Class A common stock on April 21, 2026, through the vesting of restricted stock units at no cost, bringing his total beneficial ownership to 1,215 shares.
An additional 369 restricted stock units vested on the same date, indicating a scheduled equity compensation event that will convert to shares upon the earlier of the first anniversary or the company's next annual stockholders meeting.
The transaction represents routine equity compensation vesting rather than discretionary insider buying, suggesting confidence maintenance in the company but not a strong conviction buy signal from management.

Insider Trading Filed: 2026-04-23

Key Insights

Director Melinda Litherland acquired 776 shares of Bio-Rad Class A common stock through the vesting of restricted stock units (369 shares vested on 4/21/2026, with an additional 407 shares acquired on the same date), indicating routine equity compensation rather than discretionary market purchases.
The RSU vesting structure shows a one-year vesting schedule tied to the earlier of the first anniversary or next annual shareholder meeting, which is a standard director compensation practice with no immediate cash outlay required.
This transaction represents an insider acquisition through equity compensation, which is typically viewed neutrally as it reflects predetermined compensation plans rather than speculative trading activity or loss of confidence in the company.

Current Report Filed: 2026-02-19

Key Insights

Sartorius AG, in which Bio-Rad Laboratories has an investment, reported strong financial results for the year ended December 31, 2025, with increases in sales revenue, gross profit, EBIT, and net profit.
Sartorius AG's cash flow from operating activities was robust at €837.0 million, indicating the company's ability to generate cash from its operations.
Bio-Rad's investment in Sartorius AG continues to be a significant contributor to its financial performance, as evidenced by the detailed financial information provided in the 8-K filing.

Annual Report Filed: 2026-02-13

Key Insights

Bio-Rad Laboratories, Inc. reported stable revenue and profitability in fiscal year 2025, with consistent performance across its key business segments.
The company maintained a strong balance sheet, with solid liquidity and manageable debt levels, positioning it well for future investments and growth opportunities.
Bio-Rad's research and development spending remained elevated, indicating a focus on innovation and new product development to drive long-term competitiveness.

Current Report Filed: 2026-02-12

Key Insights

The company announced its financial results for the quarter ended December 31, 2025, which could provide insight into its recent performance.
The company posted supplemental earnings materials on its website, which may contain additional details on the quarterly results.
The filing does not mention any material agreements, leadership changes, or earnings surprises, suggesting a routine quarterly report.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information